Navigation Links
Cytochroma Appoints Dr. John Cunningham to its Scientific Advisory Board
Date:10/15/2009

MARKHAM, ON, Oct. 15 /PRNewswire/ - Cytochroma today announced that it has appointed John Cunningham, CVO, BM BCh, DM, FRCP, to the Company's Scientific Advisory Board.

Dr. Cunningham is Professor of Nephrology at the UCL Medical School, London and Consultant Nephrologist at the Royal Free Hospital, London. His early training was at Cambridge and Oxford Universities, with postgraduate training in The University of London and Washington University School of Medicine, St. Louis, USA. In 2005, he was appointed to the position of Physician to HM the Queen. Dr. Cunningham has extensive experience in the fields of hypertension, renal stone disease, acute and chronic kidney disease, renal transplantation and dialysis, and metabolic bone disease. He has published in excess of 100 peer reviewed scientific articles, is a visiting professor to various universities in Europe, Australia, and the United States, a member of numerous international expert panels and working groups, and a national and international lecturer.

"We are delighted and honored that Dr. Cunningham has agreed to advise Cytochroma on its efforts to develop new drugs for secondary hyperparathyroidism in chronic kidney disease patients," said Charles W. Bishop, Ph.D., President and Chief Executive Officer of Cytochroma. "Dr. Cunningham's wealth of knowledge and clinical experience will be invaluable as we move our products through mid- and late-stage clinical trials."

    Other members of Cytochroma's Scientific Advisory Board include:

    -   Geoff Block, MD - Director of Clinical Research, Denver Nephrology

    -   David Allen Bushinsky, MD - Professor of Medicine and of Pharmacology
        and Physiology, University of Rochester School of Medicine, and
        Chief, Nephrology Division, University of Rochester Medical Center

    -   Russell Chesney, MD - Le Bonheur Professor and Chair, Department of
        Pediatrics, University of Tennessee Health Science Center

    -   Bess Dawson-Hughes, MD - Professor of Medicine, Tufts University
        School of Medicine, and Senior Scientist and Director, Bone
        Metabolism Laboratory Jean Mayer USDA Human Nutrition Research Center
        on Aging at Tufts University

    -   Glenville Jones, PhD - Head of Biochemistry Department, Professor of
        Biochemistry & Medicine, Queen's University, Kingston, Ontario

    -   Kevin Martin, MD - Director of Research, Division of Nephrology, St.
        Louis University School of Medicine

    -   L. Darryl Quarles, MD - Vice Chairman for Research, Department of
        Internal Medicine, and Director, The Kidney Institute and Division of
        Nephrology at the University of Kansas Medical Center

    -   Isidro Salusky, MD - Professor of Pediatric Medicine, David Geffen
        School of Medicine, and Director of Clinical Research Center, UCLA
        School of Medicine

    -   Stuart Sprague, MD - Professor of Medicine, Feinburg School of
        Medicine, and Chief, Division of Nephrology & Hypertension, Evanston
        Northwestern Healthcare, Northwestern University

    About Cytochroma

Cytochroma is a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary products to treat and prevent the clinical consequences of vitamin D insufficiency and secondary hyperparathyroidism (SHPT) associated with chronic kidney disease (CKD). The Company specializes in developing new vitamin D therapies which are designed to safely and effectively treat patients with stage 3, 4 or 5 CKD. Cytochroma has three lead product candidates in clinical development for CKD patients: CTA018 Injection and CTAP201 Injection are being developed for the treatment of SHPT in stage 5 CKD, while CTAP101 Capsules are being developed for the treatment of vitamin D insufficiency and associated SHPT in stage 3 and 4 CKD. CTA018 Injection is being developed in partnership with Mitsubishi Tanabe Pharma Corporation for the U.S. and Asian markets, and Cytochroma retains co-promotion rights for this product in the U.S. In addition, Cytochroma is developing novel therapies to treat hyperphosphatemia in CKD patients.

SOURCE Cytochroma


'/>"/>
SOURCE Cytochroma
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cytochroma announces appointment of Ulrik Spork to Board of Directors
2. Cytochroma appoints Steven I. Engel as Vice President of Regulatory Affairs and Quality Assurance
3. Cytochroma and Mitsubishi Tanabe form partnership for chronic kidney disease therapies in U.S. and Asia
4. Cytochroma Closes $45 Million Series C Financing
5. Cytochroma Appoints R. Richard Wieland II As CFO
6. Cytochroma opens U.S. headquarters in Illinois
7. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
8. Sundia Appoints Charles D. Maher as Senior Vice President of Sales and Marketing
9. CalciMedica Appoints Evelyn Graham to its Board of Directors
10. Resverlogix Appoints A. Brad Cann as Chief Financial Officer
11. Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... 10, 2016 , ... Benchmark Research, a fully-integrated network of ... long-standing principal investigators (PI) to the roles of Chief Medical Officer, Clinical Research ... Laurence Chu, a Benchmark Research PI in the Austin office, will assume the ...
(Date:2/10/2016)... ... 10, 2016 , ... PatientCrossroads announces that the ... online PatientCrossroads platform, has exceeded both its one-year and overall recruitment goals since ... which seeks to advance understanding of the hereditary risks for certain kinds of ...
(Date:2/10/2016)... , ... February 09, 2016 , ... ... and current winner of the Highest Overall Customer Rating Award from Circuits ... of its business units across the USA, Canada, Mexico and China. , The ...
(Date:2/9/2016)... ... February 08, 2016 , ... Net-Translators, ... today the launch of its revamped and improved website. In an on-going effort ... the redesigned website will better communicate how the company designs and delivers thorough, ...
Breaking Biology Technology:
(Date:1/28/2016)... Synaptics (NASDAQ: SYNA ), a leading developer of human interface ... 31, 2015. --> --> ... percent compared to the comparable quarter last year to $470.5 million. ... million, or $0.93 per diluted share. --> ... of fiscal 2016 grew 9 percent over the prior year period ...
(Date:1/25/2016)... Unisys Corporation (NYSE: UIS ) today announced the implementation ... New York City , to help U.S. ... the United States using passports that are ... of the system at Dulles last year. The system will ... 2016. --> pilot testing of the system at ...
(Date:1/22/2016)... , January 22, 2016 ... the addition of the  "Global Behavioral ... offering. --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) ... "Global Behavioral Biometric Market 2016-2020"  report ... Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has ...
Breaking Biology News(10 mins):